Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Federico Cappuzzo, Denis Moro‐Sibilot et al.|The Lancet Respiratory Medicine|2019Cited by 937